Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.64 |
| ▸ | IDO1 | P14902 | 17/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096593 | 1.00 | CYP11B2 (0.64) | CYP11B2IDO1TDO2TNKS | |
| SCHEMBL1096905 | 0.91 | CYP11B2 (0.61) | CYP11B2IDO1TDO2TNKS | |
| SCHEMBL1098252 | 0.91 | CYP11B2 (0.61) | CYP11B2IDO1TDO2TNKS | |
| SCHEMBL1096909 | 0.89 | CYP11B2 (0.65) | CYP11B2IDO1TDO2TNKS | |
| SCHEMBL1096744 | 0.89 | CYP11B2 (0.65) | CYP11B2IDO1TDO2TNKS | |
| SCHEMBL8234413 | 0.88 | CYP11B2 (0.61) | CYP11B2IDO1TDO2 | |
| SCHEMBL1097383 | 0.88 | CYP11B2 (0.61) | CYP11B2IDO1TDO2TNKS | |
| SCHEMBL1097977 | 0.88 | CYP11B2 (0.61) | CYP11B2IDO1TDO2TNKS | |
| SCHEMBL1095921 | 0.88 | CYP11B2 (0.61) | CYP11B2IDO1TDO2TNKS | |
| SCHEMBL1095918 | 0.88 | CYP11B2 (0.61) | CYP11B2IDO1TDO2TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301931-B1 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| EP-2301931-A1 | Imidazoles as aldosterone synthase inhibitors | Novartis AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2001866-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007117982-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182007-A1 | ORGANIC COMPOUNDS | REN, CYP17A1, HSD17B1 | CYP11B2 28/4885IDO1 2430/4885TDO2 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.